EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Five-Year Survival and Determinants of Diffuse Large B-cell Lymphoma in Resource-Limited Settings: The Impact of HIV/AIDS in a Multi-Center Cohort Study

Abel Temeche Kassaw iD, Ephrem Tafesse Teferi, Getachew Yitayew Tarekegn, Tigabu Eskeziya Zerihun, Samuel Agegnew Wondm, Tilaye Arega Moges, Woretaw Sisay Zewdu, Tesfaye Yimer Tadesse, Desalegn Addis Mussie, Teferi Bihonegn Melese, Samuel Berihun Dagnew, Mekuanent Kassa Birarra

Cancer Control · 2026-03 · 33

DOI: 10.1177/10732748261434396 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Control, online erschienen am 14.03.2026. Verfasst von Abel Temeche Kassaw und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabo…. Hauptthemen laut MEDLINE: HIV Infections, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma and a leading cause of cancer-related mortality worldwide. Evidence on long-term survival and prognostic determinants remains limited, particularly among people living with HIV. This study evaluated survival outcomes and predictors of mortality among adults with DLBCL in Northwest Ethiopia.

Methods

We conducted a multicenter retrospective cohort study of consecutively enrolled adults with newly histologically confirmed DLBCL diagnosed between August 1, 2020, and July 31, 2025, at three referral hospitals in Northwest Ethiopia. Patients were followed from diagnosis until death, loss to follow-up, or study end. Overall survival (OS) was estimated using the Kaplan–Meier method. Cox proportional hazard regression was used to identify independent predictors of mortality. Subgroup analyses were performed depending on HIV status. Statistical significance was set at P ≤0.05.

Results

A total of 175 patients with DLBCL were included, of whom 31 (17.7%) were HIV-positive. The median survival time was 36 months (IQR: 21–49). The estimated 5-year OS was 25%. Advanced disease (stage IV; AHR = 2.7, 95% CI: 1.1–6.5), HIV-positive status (AHR = 2.3, 95% CI: 1.1–5.0), elevated serum lactate dehydrogenase (LDH) (≥2× upper limit of normal; AHR = 2.2, 95% CI: 1.0–4.9), and delayed initiation of chemotherapy (≥2 months; AHR = 2.6, 95% CI: 1.2–5.8) were independently associated with increased mortality. Among HIV-positive patients, neutropenic fever was the sole independent predictor of death (AHR = 4.3, 95% CI: 1.1–17.4).

Conclusions

Survival among patients with DLBCL in Northwest Ethiopia remains poor, particularly among those presenting with advanced disease, those living with HIV, those that have delayed treatment initiation, and those that have elevated serum LDH – all these parameters were independently associated with increased mortality. Strengthening diagnostic capacity, ensuring equitable access to immunochemotherapy, integrating HIV–oncology services, and prioritizing early treatment initiation are essential to improving outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsLymphoma, Large B-Cell, DiffuseAdultFemaleHumansMaleMiddle AgedEthiopiaPrognosisResource-Limited SettingsRetrospective StudiesCohort Studies

Stichwörter der Autor:innen

DLBCLEthiopiaHIV-associated lymphomadiffuse large B-cell lymphomarituximabsurvival

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
  • Department of Internal Medicine, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
  • Department of Clinical Pharmacy, College of Health Science, Debre Tabor University, Debre Tabor, Ethiopia.
  • Department of Pharmacology and Toxicology, Pharmacy Education and Clinical Service Directorate, Debre Tabor University, Debre Tabor, Ethiopia.
  • Department of Pharmacy, College of Health Science, Debre Tabor University, Debre Tabor, Ethiopia.
  • Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

ORCID-Profile: Abel Temeche Kassaw

Zitieren

APA

Kassaw, A. T., Teferi, E. T., Tarekegn, G. Y., Zerihun, T. E., Wondm, S. A., Moges, T. A., Zewdu, W. S., Tadesse, T. Y., Mussie, D. A., Melese, T. B., Dagnew, S. B., & Birarra, M. K. (2026). Five-Year Survival and Determinants of Diffuse Large B-cell Lymphoma in Resource-Limited Settings: The Impact of HIV/AIDS in a Multi-Center Cohort Study. Cancer Control, 33. https://doi.org/10.1177/10732748261434396

Vancouver

Kassaw AT, Teferi ET, Tarekegn GY, Zerihun TE, Wondm SA, Moges TA, et al. Five-Year Survival and Determinants of Diffuse Large B-cell Lymphoma in Resource-Limited Settings: The Impact of HIV/AIDS in a Multi-Center Cohort Study. Cancer Control. 2026;33. doi:10.1177/10732748261434396

BibTeX
@article{Kassaw2026,
  author = {Kassaw, Abel Temeche and Teferi, Ephrem Tafesse and Tarekegn, Getachew Yitayew and Zerihun, Tigabu Eskeziya and Wondm, Samuel Agegnew and Moges, Tilaye Arega and Zewdu, Woretaw Sisay and Tadesse, Tesfaye Yimer and Mussie, Desalegn Addis and Melese, Teferi Bihonegn and Dagnew, Samuel Berihun and Birarra, Mekuanent Kassa},
  title = {Five-Year Survival and Determinants of Diffuse Large B-cell Lymphoma in Resource-Limited Settings: The Impact of HIV/AIDS in a Multi-Center Cohort Study},
  journal = {Cancer Control},
  year = {2026},
  volume = {33},
  doi = {10.1177/10732748261434396}
}
Kostenlos starten →